[go: up one dir, main page]

CO5150205A1 - METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT - Google Patents

METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT

Info

Publication number
CO5150205A1
CO5150205A1 CO00016009A CO00016009A CO5150205A1 CO 5150205 A1 CO5150205 A1 CO 5150205A1 CO 00016009 A CO00016009 A CO 00016009A CO 00016009 A CO00016009 A CO 00016009A CO 5150205 A1 CO5150205 A1 CO 5150205A1
Authority
CO
Colombia
Prior art keywords
agonist
selective
treatment
subject
requires
Prior art date
Application number
CO00016009A
Other languages
Spanish (es)
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5150205A1 publication Critical patent/CO5150205A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a nuevos métodos de aumentar el volumen óseo que comprenden administrar un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere de tal tratamiento.Esta invención se refiere adicionalmente a un método para tratar o prevenir trastornos óseos que comprende administrar un agonista EP1 selectivo que no ocurre naturalmente a un sujeto que requiere tal tratamiento.<EMI FILE="00016009_1" ID="1" IMF=JPEG >The present invention relates to new methods of increasing bone volume comprising administering a selective EP1 agonist that does not occur naturally to a subject requiring such treatment.This invention further relates to a method for treating or preventing bone disorders comprising administering a selective EP1 agonist that does not naturally occur to a subject that requires such treatment. <EMI FILE = "00016009_1" ID = "1" MFI = JPEG>

CO00016009A 1999-03-05 2000-03-06 METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT CO5150205A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12306399P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
CO5150205A1 true CO5150205A1 (en) 2002-04-29

Family

ID=22406507

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00016009A CO5150205A1 (en) 1999-03-05 2000-03-06 METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT

Country Status (10)

Country Link
EP (1) EP1158969A2 (en)
JP (1) JP2002538105A (en)
AU (1) AU3711900A (en)
CA (1) CA2366755A1 (en)
CO (1) CO5150205A1 (en)
IL (1) IL145128A0 (en)
NO (1) NO20014192L (en)
NZ (1) NZ513828A (en)
PE (1) PE20001552A1 (en)
WO (1) WO2000051585A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080000647A (en) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 Percutaneous Absorption Formulation
JP5262720B2 (en) 2006-10-26 2013-08-14 小野薬品工業株式会社 Patch
EP2305304A4 (en) 2008-04-28 2011-08-10 Nat University Corp Hamamatsu University School Of Medicine IMMUNOSTIMULANT COMPRISING THE EP1 AGONIST
CA2792161A1 (en) * 2010-03-05 2011-09-09 University Of Rochester Ep1 inhibition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3982016A (en) * 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
AU2146592A (en) * 1991-05-29 1993-01-08 Sepracor, Inc. Combination of nsaids and prostaglandins and uses therefor
HUP0004581A2 (en) * 1997-09-09 2001-05-28 The Procter & Gamble Co. Method of increasing bone volume using non-naturally-occurring fp selective agonists
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
WO2000051616A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives

Also Published As

Publication number Publication date
WO2000051585A2 (en) 2000-09-08
EP1158969A2 (en) 2001-12-05
WO2000051585A3 (en) 2001-01-25
AU3711900A (en) 2000-09-21
NO20014192L (en) 2001-11-05
IL145128A0 (en) 2002-06-30
CA2366755A1 (en) 2000-09-08
JP2002538105A (en) 2002-11-12
NO20014192D0 (en) 2001-08-29
PE20001552A1 (en) 2001-01-30
NZ513828A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
DK1265630T3 (en) Use of insulin for the treatment of cartilage disease
EP1391838A4 (en) INSURANCE SYSTEM
BR9811780A (en) Bone volume increase method using non-naturally occurring selective fp agonists
CO5221115A1 (en) NEW FUNGICIDE COMPOUNDS
EP1205154A3 (en) Osteosynthesis plating apparatus and method with extension plate
BR0318600A (en) implantable assembly for osteosynthesis, and assembly with at least two osteosynthesis plates and bone screws
EP1129675A3 (en) Scaffold fixation device for use in articular cartilage repair
WO2004032988A3 (en) Coupling agents for orthopedic biomaterials
BR9814923A (en) Method for treating alzheimer&#39;s disease
BR0114758A (en) Ep4 receptor inhibitors for rheumatoid arthritis treatment
BR0315597A (en) Low-dose processes for treating disorders where tnf (alpha) activity is harmful
BR0009776A (en) Treatment method
CO5271724A1 (en) USE OF PROSTAGLANDIN AGONISTS TO TREAT ERECTILE DYSFUNCTION OR IMPOTENCE
BR9913705A (en) Methods for the treatment of multiple myeloma and bone tissue resorption induced by myeloma using integrin antagonists
EP1173470A4 (en) Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
CO5150205A1 (en) METHODS OF INCREASING THE OSEO VOLUME THAT INCLUDES MANAGING AN SELECTIVE EP1 AGONIST THAT DOES NOT NATURALLY OCCUR TO A SUBJECT THAT REQUIRES SUCH TREATMENT
CO5150178A1 (en) ELETRIPTAN MONOHIDRATE BROMOHYDRATE AND PROCEDURE FOR PREPARATION
BR0013416A (en) Drug, use of a drug selected from the group consisting of at least one bisphosphonate, and method for treating a fractured bone
GB2331301C (en) Galanin
TR200103418T2 (en) Therapeutic use of melatonin.
WO2000012047A3 (en) Enhancement of return to independent living status with a growth hormone secretagogue
PT1152757E (en) MMP INHIBITORS IN CONJUNCTIVE TISSUE GROUNDING
CO5150213A1 (en) ORAL SERTRALINE CONCENTRATE
CO5140078A1 (en) COMPOSITION AND METHOD TO TREAT ALLERGIC DISEASES RESPIRATORY DAYS THAT INCLUDE COMBINATIONS OF ANTAGONIS TAS OF RECEIVERS OF NEUROQUININE AND HISTAMINE
EP1060744A4 (en) AGENTS FOR PREVENTING / TREATING OSTEOPOROSIS